Evidence map›Paper›PMID 37928360›Full record

ArticleGlobal heart2023

Latin-American Registry of Cardiovascular Disease and COVID-19: Final Results.

Juan Esteban Gomez-Mesa, Stephania Galindo, Manuela Escalante-Forero, Yorlany Rodas, Andrea Valencia, Eduardo Perna, Alexander Romero, Iván Mendoza, Fernando Wyss, José Luis Barisani and 3 more

Abstract read
In one paragraph

Article in Global heart, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Juan Esteban Gomez-MesaFundación Valle del Lili, Cali, CO.ORCID 0000-0002-6635-6224
Stephania GalindoFundación Valle del Lili, Cali, CO.ORCID 0000-0002-6347-0996
Manuela Escalante-ForeroFundación Valle del Lili, Cali, CO.ORCID 0000-0002-2822-0887
Yorlany RodasFundación Valle del Lili, Cali, CO.ORCID 0000-0002-7344-6156
Andrea ValenciaFundación Valle del Lili, Cali, CO.ORCID 0000-0001-6855-207X
Eduardo PernaInstituto de Cardiología J.F Cabral, Corrientes, AR.ORCID 0000-0002-9977-7623
Alexander RomeroHospital Santo Tomas, Ciudad de Panama, PA.ORCID 0000-0002-0785-0804
Iván MendozaUniversidad Central de Venezuela, Caracas, VE.ORCID 0000-0002-9098-8424
Fernando WyssServicios y Tecnología Cardiovascular de Guatemala S.A -Cardiosolutions, Ciudad de Guatemala, GT.ORCID 0000-0003-1700-4692
José Luis BarisaniClínica Adventista Belgrano, Buenos Aires, AR.ORCID 0000-0002-2206-8466
Mario SperanzaHospital Clínica Bíblica, San Jose, CR.ORCID 0000-0002-6947-0735
Walter AlarcoInstituto Nacional Cardiovascular INCOR ESSALUD, Lima, PE.ORCID 0000-0001-5881-4080
Noel Alberto FlórezFundación Valle del Lili, Cali, CO.ORCID 0000-0001-8714-7168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Socioeconomic factors contribute to a more severe impact of COVID-19 in Latin American and Caribbean (LA&C) countries than in developed countries. Patients with a severe or critical illness can develop respiratory and cardiovascular complications. Objective: To describe a LA&C population with COVID-19 to provide information related to this disease, in-hospital cardiovascular complications, and in-hospital mortality. Methods: The CARDIO COVID-19-20 Registry is an observational, multicenter, prospective, and hospital-based registry of patients with confirmed COVID-19 infection that required in-hospital treatment in LA&C. Enrollment of patients started on May 01, 2020, and ended on June 30, 2021. Results: The CARDIO COVID-19-20 Registry included 3260 patients from 44 institutions of 14 LA&C countries. 63.2% patients were male and median age was 61.0 years old. Most common comorbidities were overweight/obesity (49.7%), hypertension (49.0%), and diabetes mellitus (26.7%). Most frequent cardiovascular complications during hospitalization or reported at discharge were cardiac arrhythmia (9.1%), decompensated heart failure (8.5%), and pulmonary embolism (3.9%). The number of patients admitted to the Intensive Care Unit (ICU) was 1745 (53.5%), and median length of their stay at the ICU was 10.0 days. Support required in ICU included invasive mechanical ventilation (34.2%), vasopressors (27.6%), inotropics (10.3%), and vasodilators (3.7%). Rehospitalization after 30-day post discharge was 7.3%. In-hospital mortality and 30-day post discharge were 25.5% and 2.6%, respectively. Conclusions: According to our findings, more than half of the LA&C population with COVID-19 assessed required management in ICU, with higher requirement of invasive mechanical ventilation and vasoactive support, resulting in a high in-hospital mortality and a considerable high 30-day post discharge rehospitalization and mortality.

Indexed as

Cardiovascular DiseasesCOVID-19AftercareFemaleHumansIntensive Care UnitsMaleMiddle AgedMulticenter Studies as TopicObservational Studies as TopicPatient DischargeProspective StudiesSARS-CoV-2CaribbeanCoronavirusCOVID-19Heart FailureLatin AmericaSARS-CoV-2

Identifiers

PMID37928360
PMCPMC10624135

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.